Journal of Hebei Medical University
Previous Articles Next Articles
Online:
Published:
Abstract: [Abstract] Objective〖HTSS〗〓To investigate the characteristics and associated factors of the adverse reactions of gallstones caused by ceftriaxone sodium so as to provide references and evidences for clinical rational use of ceftriaxone sodium. 〖HTH〗〖WTHZ〗Methods〖HTSS〗〓The adverse reactions of cholecystolithiasis caused by ceftriaxone sodium reported in domestic journal from January 1990 to August 2015 were analyzed statistically. 〖HTH〗〖WTHZ〗Results〖HTSS〗〓A total of 40 publications were eligible for this analysis, and 1 027 ceftriaxone sodiuminduced cholecystolithiasis cases were collected,which can be diagnosed gallstones by ultrasound or CT examination. The adverse reactions were often seen in males than in females and partically seen in pediatric patients (164 cases), which should be given highly attention. Overdose was a major factor leading to the onset of gallstones, especially when doses exceed the specification, the proportion of adverse reactions will be increased. Gallstones will occur within 15 days after administration of ceftriaxone sodium, especially the incidence was relatively higher when continuous administration for 3-7 d. In different forms of gallstones, 454 patients showed sediment types. After stopping administrating, gallstones will disappear within 8-14 d without special treatment. 〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓Great attention should be paid to ceftriaxone sodiuminduced cholecystolithiasis. The clinical manifestation of the patients should be closely observed. Once the pseudostone of the gallbladder is found, ceftriaxone sodium should be discontinued immediately and then treated with other methods.
Key words: cholecystolithiasis, ceftriaxone, drug toxicity
WANG Chuncheng1, TANG Yufei2, BAO Lei1, WEN Junye1, CAO Yuemin1*, ZHANG Wanxing1.
0 / / Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: https://xuebao.hebmu.edu.cn/EN/10.3969/j.issn.10073205.2018.03.006
https://xuebao.hebmu.edu.cn/EN/Y2018/V38/I3/272